Metastatic Breast Cancer Clinical Trials in Grand Rapids, Michigan

3 studies are recruiting for metastatic breast cancer in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hor…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Midwest, LLC, Grand Rapids, Michigan
    Locations
    79 in total
    Run by
    BioNTech SE

    See if you can join NCT06827236 on ClinicalTrials.gov

  2. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treat…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan
    Locations
    224 in total
    Run by
    LeonaBio

    See if you can join NCT05696626 on ClinicalTrials.gov

  3. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer age…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START - Midwest, Grand Rapids, Michigan
    Locations
    8 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT06784193 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.